China Medical System Holdings Ltd
SWB:2M7C
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
QVC Group Inc
OTC:QVCGB
|
US |
|
A
|
Asiro Inc
TSE:7378
|
JP |
|
M
|
MKH Oil Palm East Kalimantan Bhd
KLSE:MKHOP
|
MY |
|
S
|
SE Power Ltd
NSE:SEPOWER
|
IN |
|
Carpenter Technology Corp
NYSE:CRS
|
US |
|
Kforce Inc
NYSE:KFRC
|
US |
|
V
|
Vistra Corp
SWB:0V6
|
US |
|
Nederman Holding AB
STO:NMAN
|
SE |
China Medical System Holdings Ltd
Other
China Medical System Holdings Ltd
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
China Medical System Holdings Ltd
SWB:2M7C
|
Other
¥88.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
Other
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Other
-HK$215.8m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Other
¥68.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Other
-HK$10.5B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
China Medical System Holdings Ltd
Glance View
China Medical System Holdings Ltd., a prominent player in the pharmaceutical industry, weaves its business model around the intricate pathway of driving market expansion through innovation and strategic partnerships. Founded with a vision to bring cutting-edge and specialized medicines to the Chinese healthcare market, CMS has established itself as a stalwart distributor and marketer. The company operates by obtaining licenses and distribution rights for pharmaceutical products primarily from European and North American manufacturers. By leveraging these international partnerships, CMS effectively bridges the gap between Western innovation and Chinese demand, tailoring its portfolio to include niche and differentiated therapeutic products that cater to the evolving needs of China's healthcare landscape. At the core of CMS's revenue model lies its proficiency in brand building and market penetration. Unlike the conventional pharmaceutical giants focusing solely on R&D, CMS maximizes its profits through strategic marketing and efficient distribution networks. By prioritizing products that require expert promotion to healthcare professionals, CMS utilizes its extensive sales force to ensure these products gain maximum visibility and acceptance in the marketplace. This business model not only fosters a symbiotic relationship with international pharmaceutical partners but also sustains a robust pipeline of new offerings. Therefore, with a strategic balancing act between global pharmaceutical expertise and local market intricacies, China Medical System Holdings Ltd. continues to fortify its position as a pivotal conduit in the dissemination of specialized medical solutions across China.
See Also
What is China Medical System Holdings Ltd's Other?
Other
88.1m
CNY
Based on the financial report for Dec 31, 2025, China Medical System Holdings Ltd's Other amounts to 88.1m CNY.